Find Webinars

7,122 upcoming
MoreZoom

Topics › More Webinars

Crossing the Blood-Brain Barrier: Humanized Transport Mice for Brain-Targeted Drug Development

Free

Length
1 hr
Platform
Zoom
Topic
More Webinars

Get notified when the recording is available

We’ll email you once, when this recording is ready, with an unsubscribe link. See our privacy policy.

About this webinar

Welcome to GemPharmatech's Webinar!

Less than 1% of a systemically dosed therapeutic antibody reaches the brain. Receptor-mediated transcytosis (RMT) is the leading non-invasive answer, and Roche’s Brainshuttle™ platform has taken it into Phase 3 with trontinemab — a roughly 50-fold improvement in CNS exposure over a conventional anti-amyloid antibody.

But there’s a catch for preclinical work. Shuttle modules are engineered against human TFRC, CD98HC and IGF1R. They don’t bind the mouse receptors. In a conventional rodent, the experiment simply can’t be run.

GemPharmatech’s humanized BBB transport mice replace the mouse receptor extracellular domain with its human counterpart, so human-targeted shuttles engage as designed. Each line is characterized for receptor expression and tolerability, and crosses with established AD, PD, HD and ALS models. We pair them with a microvessel-depletion brain PK workflow that distinguishes genuine parenchymal exposure from antibody trapped in the vasculature — the difference between a real delivery result and an artifact.

In this webinar:

1. The BBB and RMT delivery strategies, with Brainshuttle™ trontinemab as the clinical proof of concept

2. Our humanized RMT target models: receptor expression and safety data, and where humanization helps and where it doesn’t

3. The full BBB model library — TFRC, CD98HC and IGF1R on healthy backgrounds and crossed into AD, PD, HD and ALS

4. Brain PK assessment and efficacy evaluation in practice: anti-Aβ antibodies and AAV-mediated delivery

More More webinars 1,745

All More →

All More (1,745)